QureTech Bio’s vision is to develop first line drugs to combat antibiotic resistance and infectious diseases. The global market for antibiotics is estimated at USD 38 billion with USA, Europe and Japan representing 50%. The cost of antibiotic resistance to medical communities in the EU alone is conservatively estimated to be €1.5 billion and the availability of new targeted antibiotics of this type would generate significant cost savings for healthcare systems.
Company Details
- Employees
- 8
- Founded
- 2010
- Address
- Tvistevägen 48c, Umeå,se-907 36,sweden
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- quretech.com
- HQ
- Umeå
Quretech Bio Ab Questions
Quretech Bio Ab's website is quretech.com
Quretech Bio Ab's LinkedIn profile is https://se.linkedin.com/company/quretech-bio-ab
Quretech Bio Ab has
8 employees.
View email and phone details for 8
employees at Quretech Bio Ab.
Quretech Bio Ab's industry is
Research Services
Quretech Bio Ab's top competitors are
Kancera,
Lipigon Pharmaceuticals Ab,
Umandiagnostics Ab - A Quanterix Company,
Techtum Lab,
Spinchem,
Lipum Ab,
Nordic Biomarker,
Umeå Biotech Incubator,
Agrisera Ab,
Apl (Apotek Produktion & Laboratorier Ab).
Quretech Bio Ab's categories are Research Services
Quretech Bio Ab's founding year is 2010
